Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30573% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Remaining authorization under share repurchase program by Year
Remaining authorization under share repurchase program ($M) ($M)
Moderna Remaining authorization under share repurchase program: $1,667M in FY2025, unchanged from a year earlier.
Latest, FY2025
1,667
Period ended Dec 31, 2025
Change on a year earlier
0.0%
1,667 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 13 (Stockholders' Equity).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Remaining authorization under share repurchase program ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,667 | 0.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 1,667 | 0.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 1,667 | -40.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 2,814 | +1,867.8% | Form 10-K (filed 2025-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 143 | – | Form 10-K (filed 2024-02-23) ↗ |
Cite this data
StockData. (2026). Moderna Remaining authorization under share repurchase program ($M), annual FY2021–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/buyback-auth-rem
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.